Value Will Pave The Way For Innovative Brands, Pfizer’s Germano Says
Global Innovative Pharma Business President Geno Germano sat down with “The Pink Sheet” to discuss growth strategy, M&A and Pfizer’s increasing focus on value in a changing health care world.
You may also be interested in...
Pfizer finished a rolling NDA for the high-profile breast cancer drug, the first-in-class CDK-4/6 inhibitor. Whether or not FDA will agree Phase II data results from the PALOMA-1 trial are sufficient to grant accelerated approval remains to be seen.
Sanofi will fill and package 100 million doses of a rival vaccine for the European market in 2021 in a sign of how the industry is working to meet an unprecedented demand for COVID-19 vaccines.
Data from a high-profile Phase III COVID-19 vaccine trial will be released the first week of February, management said.